Inventaire - dina vänner och gemenskaper är ditt bästa bibliotek

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

författare

Susanna Hegewisch-Becker

1955 -

Dirk Arnold

1966 -

Anke Reinacher-Schick

Ullrich Graeven

publicerad i: The Lancet Oncology

utgivningsår: 2015-09-08

huvudämne: phase III clinical trial, koloncancer, bevacizumab, oxaliplatin, metastatic colon cancer, colorectal carcinoma

Refererar artiklar 16

Datum

Titel

Författare

2015-04-07

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Linda Mol
2015-01-20

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
2015-10-22

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

Nicole Tubiana Mathieu, Thierry André, Dewi Vernerey, Franck Bonnetain
2014-07-23

Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis

Monika K Krzyzanowska
2014-07-31

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Ursula Vehling-Kaiser, Ludwig Fischer von Weikersthal, Tobias Heintges
2014-09-04

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dirk Arnold, ESMO Guidelines Working Group
2013-06-19

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Lars Berglund
2013-11-12

Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial

Ruchan Uslu, Orhan Sencan
2013-09-10

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham
2012-01-10

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

Eduardo Díaz-Rubio, Adelaida Lacasta, Josep Tabernero Caturla
2011-10-03

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Stud

Daniel J. Sargent
2010-06-01

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Bridget Robinson, Timothy Price, David Cunningham, Stephen Clarke, John Zalcberg
2009-09-28

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study
2008-04-01

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study

Leonard B. Saltz, Eduardo Díaz-Rubio
2006-01-01

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
2004-06-03

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Napoleone Ferrara, John D Hainsworth

Artikel - wd:Q30316174

Välkommen till Inventaire

din gemenskap och vänners bibliotek

lär mer